
    
      A Phase I/II, Open-Label, Multicentre Study to Assess the Safety, Tolerability,
      Pharmacokinetics and Anti-tumour Activity of Ascending Doses of AZD9291 in Patients with
      Advanced Non Small Cell Lung Cancer who have Progressed Following Prior Therapy with an
      Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent (AURA)
    
  